myTomorrows is a global health tech company dedicated to breaking down barriers for patients seeking treatment options.
We strive to enable earlier and better treatment access by bridging the gap between those searching for possible options, and the companies who develop them. We work closely with patients, healthcare professionals, trial sites, patient advocacy groups, and BioPharma – connecting key stakeholders in the drug development ecosystem.
We’ve developed a cutting-edge AI-powered technology platform that simplifies and streamlines access to drugs in development. To support our users and clients, we have a range of industry-expert specialized teams ready to help. Our services include clinical trial patient recruitment, Expanded Access Program management and Real-World Data collection.
With a global footprint spanning 134 countries, to date we’ve supported over 17,000 patients, 3,000 physicians and 350 sites, earning the trust of 60+ BioPharma companies. In October 2025, we closed a €25M investment with Avego Healthcare Capital to fuel our global ambitions and scale the business.
Join us in shaping the future of treatment access - making tomorrow’s therapies accessible for people who need them today.
Every day, patients, physicians, and pharma companies navigate a fragmented, slow, and complex healthcare ecosystem to find pre-approval treatments. At myTomorrows, we are building the global infrastructure to solve this. Our mission is clear: to enable earlier and better access to all possible treatment options for patients who cannot afford to wait.
Operating across 134+ countries, with hubs in Amsterdam, New York, and India, we’ve supported over 17,000 patients and 3,000+ physicians. Avego’s €25 million growth investment is our launchpad to scale the business internationally, deepen BioPharma partnerships, and build the financial architecture that a company of this complexity now requires.